SCYNEXIS, Inc. (SCYX)
SCYX moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How SCYX actually reacts to news — the realized, point-in-time move the market made, measured across 431 labeled events over the last three years with zero look-ahead.
SCYX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 417 |
| 30-min | 0.00% | 41% | 431 |
| 60-min | +0.23% | 52% | 431 |
| to close | 0.00% | 46% | 431 |
| Middle 50% of SCYX reactions | -1.16% to +1.23% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 431 |
Half of all SCYNEXIS, Inc. news events land between -1.16% and +1.23% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SCYX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | +0.34% | 60% | +0.30% |
| Rating reiterations | 12 | -0.77% | 25% | -0.13% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SCYX ranks against every other measured name →
That’s how SCYX usually reacts — get an email when it moves on news →Email me when SCYX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SCYX's baseline. Nothing else.
Recent SCYX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Press release | GlobeNewswire | +1.96% | -5.10% | |
| Form 8-K SCYNEXIS INC For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | +0.87% | |
| SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 | Press release | GlobeNewswire | -2.35% | -1.07% | |
| Form 8-K SCYNEXIS INC For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | +9.71% | |
| SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors | Press release | GlobeNewswire | +0.90% | +9.71% | |
| SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development | Press release | GlobeNewswire | +0.65% | -4.36% | |
| Form 8-K SCYNEXIS INC For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | -2.49% | |
| SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer | Press release | GlobeNewswire | +0.83% | -2.49% | |
| SCYNEXIS to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -3.19% | -3.00% | |
| SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +6.73% | +9.04% | |
| SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Press release | GlobeNewswire | +3.01% | +4.90% | |
| Form 8-K SCYNEXIS INC For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K SCYNEXIS INC For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | -4.99% | |
| Form 8-K SCYNEXIS INC For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | +0.29% | |
| SCYNEXIS Announces One-for-Eight Reverse Stock Split | Press release | GlobeNewswire | +2.35% | +0.29% | |
| Form 10-Q SCYNEXIS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.02% | +2.13% | |
| Form EFFECT SCYNEXIS INC | SEC filing · Form EFFECT | SEC EDGAR | -6.12% | -9.44% | |
| SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.02% | +2.13% | |
| SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.01% | +0.58% | |
| Form S-3 SCYNEXIS INC | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -1.58% | |
| Form ARS SCYNEXIS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.15% | +4.24% | |
| Form DEF 14A SCYNEXIS INC For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | -1.15% | +4.24% | |
| Form DEFA14A SCYNEXIS INC | SEC filing · Form DEFA14A | SEC EDGAR | -1.15% | +4.24% | |
| Form DEF 14A SCYNEXIS INC For: May 19 | SEC filing · Form DEF | SEC EDGAR | +0.09% | -0.42% | |
| Form 8-K SCYNEXIS INC For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.85% | |
| Form PRE 14A SCYNEXIS INC For: Jun 25 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -1.85% | |
| Form PRE 14A SCYNEXIS INC For: May 19 | SEC filing · Form PRE | SEC EDGAR | -1.82% | -2.73% | |
| Form 8-K SCYNEXIS INC For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +2.06% | +14.06% | |
| Form 8-K SCYNEXIS INC For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -3.29% | -2.38% | |
| Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million | Press release | Business Wire | +2.06% | +14.06% | |
| SCYNEXIS Announces $40.0 Million Private Placement | Press release | GlobeNewswire | +2.06% | +14.06% | |
| SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Press release | GlobeNewswire | +2.06% | +14.06% | |
| Form 10-K SCYNEXIS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.41% | +7.09% | |
| SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +5.41% | +7.09% | |
| SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 | Press release | GlobeNewswire | -0.95% | -4.34% | |
| SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) | Press release | GlobeNewswire | +0.96% | -3.17% | |
| SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 | Press release | GlobeNewswire | -1.36% | +1.43% | |
| SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement | Press release | GlobeNewswire | +1.42% | -1.39% | |
| SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK | Press release | GlobeNewswire | -0.51% | -2.79% | |
| Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections | Press release | GlobeNewswire | +7.10% | -0.28% | |
| Form 10-Q SCYNEXIS INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.77% | -2.76% | |
| SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.77% | -2.76% | |
| Form 8-K SCYNEXIS INC For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -1.52% | -7.25% | |
| SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study | Press release | GlobeNewswire | -1.52% | -7.25% | |
| SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) | Press release | GlobeNewswire | -10.99% | -18.94% | |
| SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) | Press release | GlobeNewswire | +0.00% | +3.44% | |
| SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025 | Press release | GlobeNewswire | +0.00% | +2.56% | |
| Form 10-Q SCYNEXIS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -7.44% | |
| SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | -7.44% | |
| Form 8-K SCYNEXIS INC For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SCYX section they belong to.
Where else SCYX is measured.
SCYX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CRH MEDICAL CORP (CRHM) | 431 | 0.00% | 39% |
| Globus Medical, Inc. Class A (GMED) | 431 | +0.02% | 51% |
| LeMaitre Vascular, Inc. (LMAT) | 430 | +0.05% | 54% |
| TRULIEVE CANNABIS CORP (TCNNF) | 429 | +0.41% | 58% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is SCYNEXIS, Inc.'s median reaction calculated?
Every labeled SCYX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 431 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of SCYX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SCYX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.